Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly.
about
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegalyMedical treatment of uterine leiomyomaUterine fibroids: current perspectivesRandomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.Current management of acromegaly.Combination of dexamethasone and a somatostatin analogue in the treatment of advanced prostate cancer.Ketorolac tromethamine formulations: an overview.Primary medical therapy for acromegaly.Innovative oral treatments of uterine leiomyomaLong-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa.Somatostatin analog therapy for severe polycystic liver disease: results after 2 years.Resistance to somatostatin analogs in acromegaly: an evolving concept?Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease.Somatostatin agonists for treatment of acromegaly.Phase III, double-blind study of depot octreotide versus placebo in the prevention of acute diarrhea in patients receiving pelvic radiation therapy: results of North Central Cancer Treatment Group N00CAGuidelines for the treatment of growth hormone excess and growth hormone deficiency in adults.Octreotide LAR: safety and tolerability issues.Octreotide for acromegaly treatment: a reappraisal.Adverse events associated with somatostatin analogs in acromegaly.Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review.Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.Effects of two different somatostatin analogs on glucose tolerance in acromegaly.[Usefulness of subcutaneous or long-acting octreotide as a predictive test and in the treatment of acromegaly].Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles.Desensitization treatment for hypersensitivity reaction to octreotide in an acromegalic patient.Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR).Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: a retrospective study.
P2860
Q26777682-7D018085-8BE4-4850-98BE-38CB491F49E7Q26824379-FCF2290E-00BD-4038-B4CB-AD74F1C48CFCQ30443242-B520F369-DA41-4790-9C94-EE06B3CDC895Q33979298-F411EBBC-028A-40B9-9F72-4685A495EC46Q34182034-42B46CA0-248B-40E0-AE50-96BE42430347Q34519166-C019A329-37CF-4010-A944-099E6FAB1EE9Q34996181-13121AE0-12DF-43BB-9BE9-B135D5D6DCA4Q35086868-16E7A88E-771E-48FE-AEE2-8DBF52700457Q35837820-2C21AF9B-6C69-41F2-943A-B7F7478642E0Q35987482-3F23978A-0D18-4CE9-AD11-B1C21ADEF38EQ36208594-E8599197-034C-4AEF-833C-1E49849F9CDFQ36428225-0F481834-1447-4AA8-B865-55FA5777D9F1Q36512574-75F994A6-05E4-4ACE-9DDE-0D84CF2C3D8DQ36626503-685F7128-6625-4CA6-B1D7-575050A88A3CQ37055473-EDFC6BE8-09C3-42BF-B769-7D8D2673EB21Q37055643-8499E117-770B-4DD6-AB18-07C12ABF8B0AQ37119415-0F40088C-46A6-4107-94EE-3AD3B32977D2Q37321948-F5BA5A02-A66F-49D4-B725-3BD79480896EQ37649647-5BBC6C08-A1C6-41FD-9F65-39DC626DCD20Q38152458-C35EF3D2-0D3C-4C16-B884-5B8AF1812129Q38548973-D4990FAF-59BA-45AD-BEB4-B5D8B8E36D6DQ42378746-79678E7B-13F2-429C-9B09-9E678F9CE755Q42482027-C1E95B85-0FC1-44D7-9D2E-3710629F44DAQ43889397-2741FC53-F896-4DB3-B568-E61DD8046E73Q44057154-9275825B-B239-40C1-9CB0-7C3A8334D431Q45217376-15501472-AF06-4716-835C-428DBAC006E4Q46542233-57F28E3D-4C7C-4DB2-A347-B809856F390CQ47726453-3B0C7ABD-0F3C-4500-9639-7E677BA1D758Q51561907-A8248857-911C-4B28-829E-CB8534F981FBQ53925916-FD741E32-4559-4AE1-9A72-E84520C62D66
P2860
Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Long-term therapy with long-ac ...... the management of acromegaly.
@en
Long-term therapy with long-acting octreotide
@nl
type
label
Long-term therapy with long-ac ...... the management of acromegaly.
@en
Long-term therapy with long-acting octreotide
@nl
prefLabel
Long-term therapy with long-ac ...... the management of acromegaly.
@en
Long-term therapy with long-acting octreotide
@nl
P2093
P2860
P1476
Long-term therapy with long-ac ...... the management of acromegaly.
@en
P2093
Lancranjan L
Sheppard MC
Stewart PM
Stewart SE
P2860
P304
P356
10.1046/J.1365-2265.1998.00389.X
P577
1998-03-01T00:00:00Z